Elevated Serum Soluble Trigger Receptor Expressed on Myeloid Cell-1 Levels in Placenta Accreta Spectrum Pregnancies

Abstract

Abstract Purpose: This study aimed to examine the association between soluble trigger receptor expressed on myeloid cell-1 (sTREM-1) levels and placenta accreta spectrum (PAS) pregnancies. Methods: A prospective case-control study was designed for this study. The study group included PAS pregnancies, and the control group had healthy singleton pregnancies. The control group consisted of healthy women with singleton pregnancies who had the same gestational age and body mass index (BMI) as the study group. Women with PAS were invited to participate in the study if they had no known systemic diseases (e.g., chronic hypertension, diabetes, hypothyroidism, and chronic renal–liver diseases), autoimmune disorders, multiple pregnancies, or fetal structural and chromosomal anomalies. They also did not have pregnancy cholestasis, preterm delivery, or chronic and active infection indications. The enzyme-linked immunosorbent assay method was used to measure the sTREM-1 level. Results: This study was conducted in the obstetrics department of a university hospital between November 2021 and January 2023. Thirty surgically and pathologically confirmed PAS pregnancies were included in the study group, and thirty healthy pregnancies were included in the control group. The plasma sTREM-1 level was significantly higher in the PAS pregnancy group than in the control group (p < 0.05). The mean sTREM-1 level in the PAS pregnancy group was 121.8 + 26.02 and 94.3 + 16.9 pg/mL in the control group. Conclusion: Our study showed that patients with PAS pregnancies had significantly higher serum sTREM-1 levels than those with healthy pregnancies. These findings provide novel insight into the potential pathophysiological processes underlying PAS disorders.